98%
921
2 minutes
20
Therapeutic vaccines offer a targeted approach to enhancing anti-tumor immunity with minimal systemic toxicity. Despite advancements in surgery, chemotherapy, radiation, and immunotherapy, colorectal cancer (CRC) remains a major clinical challenge, particularly due to the limited efficacy of immune checkpoint inhibitors outside the MSI-H subgroup. In this comprehensive review summarizes the emerging vaccine modalities for CRC, including peptide, nucleic acid, cell-based, vector-driven, and nanotechnology platforms. We discuss the barriers posed by tumor immune evasion and heterogeneity, and highlight innovative strategies designed to improve vaccine efficacy. Finally, we explore recent clinical developments and translational opportunities that position therapeutic vaccines as a promising component of future CRC immunotherapy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12297939 | PMC |
http://dx.doi.org/10.3390/vaccines13070689 | DOI Listing |
Ann Surg Oncol
September 2025
Division of Advanced Surgical Oncology, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Oncogene
September 2025
Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
There are no proven therapies for metastatic or unresectable Chromophobe Renal Cell Carcinoma (ChRCC). ChRCC is characterized by high glutathione levels and hypersensitivity to ferroptosis, an iron-dependent form of cell death characterized by peroxidation of polyunsaturated fatty acids. The underlying mechanisms leading to ferroptosis hypersensitivity are unknown.
View Article and Find Full Text PDFJ Robot Surg
September 2025
Department of Oncology, Shengli Oilfield Central Hospital, Dongying, China.
A major cause of cancer death, colorectal cancer is becoming more common in younger people. The comparative effectiveness of robotic versus laparoscopic total mesorectal excision (TME) as surgical interventions for mid-low rectal cancer following neoadjuvant chemoradiotherapy (nCRT) remains uncertain. To systematically evaluate oncological, perioperative, and survival outcomes of robotic versus laparoscopic surgery for mid-low rectal cancer following nCRT.
View Article and Find Full Text PDFBr J Cancer
September 2025
School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Background: Studies examining the association of chronic kidney disease (CKD) with cancer risk have demonstrated conflicting results.
Methods: This was an individual participant data meta-analysis including 54 international cohorts contributing to the CKD Prognosis Consortium. Included cohorts had data on albuminuria [urine albumin-to-creatinine ratio (ACR)], estimated glomerular filtration rate (eGFR), overall and site-specific cancer incidence, and established risk factors for cancer.
Exp Cell Res
September 2025
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Gastrointestinal Cancer Center, Peking University Cancer Hospital and Institute, Beijing, China. Electronic address:
Background: Enteric glial cells (EGCs) have been implicated in colorectal cancer (CRC) progression. This study aimed to develop and validate a prognostic model integrating EGC- and CRC-associated gene expression to predict patient survival, recurrence, metastasis, and therapy response.
Methods: Bulk and single-cell RNA sequencing data were analyzed, and a machine learning-based model was constructed using the RSF random forest algorithm.